当前位置:首页 - 行情中心 - 太龙药业(600222) - 财务分析 - 现金流量表

太龙药业

(600222)

  

流通市值:36.36亿  总市值:36.36亿
流通股本:5.59亿   总股本:5.59亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,113,738,616.18770,693,026.78288,022,291.481,656,679,498.41
  收到的税费返还---0
  收到其他与经营活动有关的现金7,077,632.495,131,279.372,178,580.049,618,055.51
  经营活动现金流入小计1,120,816,248.67775,824,306.15290,200,871.521,666,297,553.92
  购买商品、接受劳务支付的现金821,260,454.17585,004,398.58332,668,591.721,107,253,003.49
  支付给职工以及为职工支付的现金216,069,683.04147,807,129.6279,723,259.28303,863,376.69
  支付的各项税费58,333,324.0542,314,379.8729,115,948.6870,648,803.44
  支付其他与经营活动有关的现金114,442,730.1960,715,384.2546,345,709.42137,374,363.08
  经营活动现金流出小计1,210,106,191.45835,841,292.32487,853,509.11,619,139,546.7
  经营活动产生的现金流量净额-89,289,942.78-60,016,986.17-197,652,637.5847,158,007.22
二、投资活动产生的现金流量:
  收回投资收到的现金100,000,000100,000,000100,000,000130,076,002.79
  取得投资收益收到的现金39,259.7339,259.7339,259.7338,799,799.05
  处置固定资产、无形资产和其他长期资产收回的现金净额38,4556,855-68,621
  处置子公司及其他营业单位收到的现金净额---88,813.01
  收到的其他与投资活动有关的现金---0
  投资活动现金流入小计100,077,714.73100,046,114.73100,039,259.73169,033,235.85
  购建固定资产、无形资产和其他长期资产支付的现金7,600,890.854,963,046.053,126,238.9521,122,400.08
  投资支付的现金---147,750,000
  投资活动现金流出小计7,600,890.854,963,046.053,126,238.95168,872,400.08
  投资活动产生的现金流量净额92,476,823.8895,083,068.6896,913,020.78160,835.77
三、筹资活动产生的现金流量:
  取得借款收到的现金864,400,000635,400,000530,400,0001,038,887,940.49
  收到其他与筹资活动有关的现金978,000,000632,400,000469,500,000883,832,141.55
  筹资活动现金流入小计1,842,400,0001,267,800,000999,900,0001,922,720,082.04
  偿还债务支付的现金608,755,381.75460,895,381.75298,805,891.771,240,412,873.44
  分配股利、利润或偿付利息支付的现金50,791,935.9535,769,406.9424,066,432.1450,763,605.84
  支付其他与筹资活动有关的现金1,236,027,383.08770,242,761.74623,114,351.34646,910,152.66
  筹资活动现金流出小计1,895,574,700.781,266,907,550.43945,986,675.251,938,086,631.94
  筹资活动产生的现金流量净额-53,174,700.78892,449.5753,913,324.75-15,366,549.9
五、现金及现金等价物净增加额-49,987,819.6835,958,532.08-46,826,292.0531,952,293.09
  加:期初现金及现金等价物余额175,845,198.94175,845,198.94175,845,198.94143,892,905.85
  期末现金及现金等价物余额125,857,379.26211,803,731.02129,018,906.89175,845,198.94
补充资料:
  净利润-13,160,737.81-65,867,565.55
  资产减值准备-2,106,521.39-5,615,222.38
  固定资产和投资性房地产折旧-22,194,101.69-46,100,998.43
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-22,194,101.69-46,100,998.43
  无形资产摊销-2,382,961.86-5,894,001.28
  长期待摊费用摊销-4,676,027.44-8,760,944.66
  处置固定资产、无形资产和其他长期资产的损失---23,974
  固定资产报废损失--1,419.72-134,784.03
  公允价值变动损失--8,595,884.71--1,399,054.4
  财务费用-27,737,224.81-58,981,205.42
  投资损失-2,958,840.33-154,766.82
  递延所得税-1,084,721.85-7,916,119.87
  其中:递延所得税资产减少--114,602.69-4,895,650.98
    递延所得税负债增加-1,199,324.54-3,020,468.89
  存货的减少--120,266,170.53-9,944,921.38
  经营性应收项目的减少--6,675,276.51--218,708,643.37
  经营性应付项目的增加--3,199,312.34-23,219,412.38
  现金的期末余额-211,803,731.02-175,845,198.94
  减:现金的期初余额-175,845,198.94-143,892,905.85
  现金及现金等价物的净增加额-35,958,532.08-31,952,293.09
公告日期2026-10-312026-08-282026-04-302026-04-15
审计意见(境内)标准无保留意见
TOP↑